医学
慢性阻塞性肺病
慢性支气管炎
支气管扩张
囊性纤维化
哮喘
病理生理学
支气管炎
气道
免疫学
表型
疾病
重症监护医学
增强剂
生物信息学
肺
内科学
生物
麻醉
基因
生物化学
作者
George Marty Solomon,Lianwu Fu,Steven Mark Rowe,James F. Collawn
标识
DOI:10.1016/j.coph.2017.09.013
摘要
Airways diseases, especially chronic obstructive pulmonary disease (COPD) and asthma, are common causes of morbidity and mortality worldwide. There is an ongoing unmet need for novel and effective therapies. There is an established pathophysiological link and phenotypic similarity between the chronic bronchitis phenotype of COPD and cystic fibrosis (CF). New evidence suggests that CFTR dysfunction may play a role in other common airways diseases such as COPD, non-atopic asthma and non-CF bronchiectasis. Newly approved and investigational drugs that target both mutant and wild-type CFTR channels have provided a new treatment opportunity addressing the mucus defect in pulmonary diseases that share the same pathophysiology with CF.
科研通智能强力驱动
Strongly Powered by AbleSci AI